Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Janux Therapeutics (JANX) Change in Account Payables (2020 - 2025)

Historic Change in Account Payables for Janux Therapeutics (JANX) over the last 6 years, with Q3 2025 value amounting to -$168000.0.

  • Janux Therapeutics' Change in Account Payables fell 11429.79% to -$168000.0 in Q3 2025 from the same period last year, while for Sep 2025 it was $867000.0, marking a year-over-year increase of 14630.68%. This contributed to the annual value of $1.6 million for FY2024, which is 47184.12% up from last year.
  • Latest data reveals that Janux Therapeutics reported Change in Account Payables of -$168000.0 as of Q3 2025, which was down 11429.79% from $1.1 million recorded in Q2 2025.
  • Janux Therapeutics' Change in Account Payables' 5-year high stood at $2.6 million during Q3 2021, with a 5-year trough of -$1.6 million in Q1 2025.
  • Over the past 5 years, Janux Therapeutics' median Change in Account Payables value was -$107000.0 (recorded in 2023), while the average stood at $158631.6.
  • Its Change in Account Payables has fluctuated over the past 5 years, first skyrocketed by 564222.22% in 2021, then tumbled by 32616.82% in 2024.
  • Over the past 5 years, Janux Therapeutics' Change in Account Payables (Quarter) stood at -$482000.0 in 2021, then soared by 146.27% to $223000.0 in 2022, then soared by 46.64% to $327000.0 in 2023, then skyrocketed by 376.76% to $1.6 million in 2024, then crashed by 110.78% to -$168000.0 in 2025.
  • Its Change in Account Payables was -$168000.0 in Q3 2025, compared to $1.1 million in Q2 2025 and -$1.6 million in Q1 2025.